Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT07109726

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Sponsor: Terremoto Biosciences Inc.

Conditions Breast Cancer Cervical Cancer Endometrial Cancer Esophageal Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma Lung Squamous Cell Carcinoma Ovarian Cancer Solid Tumor

Interventions Fulvestrant injection TER-2013

Updated 6 times since 2025 Last updated: Feb 26, 2026 Started: Sep 23, 2025 Primary completion: Dec 30, 2028 Completion: Feb 28, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07109726, this PHASE1/PHASE2 trial focuses on Breast Cancer and Cervical Cancer and remains actively recruiting participants. Sponsored by Terremoto Biosciences Inc., it has been updated 6 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 1 earlier version

Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Terremoto Biosciences Inc.

Data source: Terremoto Biosciences Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Boston, United States , Cleveland, United States , Fairfax, United States , Houston, United States , Huntersville, United States , Nashville, United States , Omaha, United States , Orlando, United States , Rochester, United States and 4 more locations